Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Novo Nordisk A/S
Industry Sector: HealthTechnology
CEO: Lars Fruergaard Jørgensen, MBA
Number Of Employees: 76,302
Enterprise Value: $399,849,078,864
PE Ratio: 18.53
Exchange/Ticker 1: CSE:NOVO B
Exchange/Ticker 2: NYSE:NVO
Latest Market Cap: $283,871,724,942
BioCentury | Apr 9, 2025
Data Byte
Early pains, late gains for biopharmas on Wall Street
Biotech and pharma indexes reacted to a pair of signals from the White House on tariffs, resulting in a drastic turnaround
BioCentury | Apr 1, 2025
Deals
Novo, Merck each pay $200M for pipeline additions: Deals Report
Pharmas enter nine-figure upfront deals in metabolic, cardiovascular areas; plus, Bluebird will consider competing buyout offer
BioCentury | Mar 26, 2025
Finance
Early lessons from the NewCo Model
Panelists on a Capital Markets Preview webinar from BioCentury and Oppenheimer debate the hottest trend in dealmaking
BioCentury | Mar 26, 2025
Data Byte
China deals look beyond cancer
At least eight East-to-West licensing deals outside oncology so far this year
BioCentury | Mar 25, 2025
Finance
Sofinnova’s ‘pan-European’ play, China innovation and Trump’s tariff threat — a BioCentury podcast
How Biovelocita became the largest life sciences accelerator in Europe, the latest at FDA and more
BioCentury | Mar 25, 2025
Deals
Novo buys into obesity triple mechanism; AZ deepens China ties: Deals Report
Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more
BioCentury | Mar 20, 2025
Data Byte
FDA’s new and supplemental approvals in February
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Mar 12, 2025
Deals
Chasing amylin: Must-have obesity target key to Roche-Zealand deal
Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target
BioCentury | Mar 12, 2025
Product Development
Oral peptide win for Protagonist/J&J, Beam’s base editor POC, and more: Clinical Report
Protagonist data led to week’s biggest share price gain, while Arvinas saw biggest loss: in BioCentury’s latest Clinical Report
BioCentury | Mar 11, 2025
Politics, Policy & Law
Makary’s FDA agenda, amylin in obesity and life after DEI
Pending confirmation for new head of FDA will cap a tumultuous transition
Items per page:
1 - 10 of 1630